Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 12,
  • 13,
  • 13,
  • 14,
  • 15 and
BMC Cancer201919:366

https://doi.org/10.1186/s12885-019-5568-6

  • Received: 2 April 2019
  • Accepted: 2 April 2019
  • Published:

The original article was published in BMC Cancer 2017 17:332

Correction to: BMC Cancer

DOI 10.1186/s12885-017-3286-5

Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:

Fig. 1 Swimlane plot of time to response, treatment duration, and duration of follow-up for efficacy-evaluable patients who achieved response in the mBCC cohort (a), those in the laBCC cohort with treatment duration > 20 months (b), and those in the laBCC cohort who were treated for < 20 months (c). laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
(2)
Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA
(3)
Service de Dermatologie, Hôpital Saint-Louis, 1 av claude Vellefaux, 75010 Paris, France
(4)
Studienzentrum Dermatologische Onkologie, Universitätsklinikum Tübingen, Liebermeisterstr. 25, 72074 Tübingen, Germany
(5)
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080 Würzburg, Germany
(6)
University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
(7)
Department of Dermatology, University of Pennsylvania Medical Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
(8)
Clinique de Dermatologie, Hôpital Claude Huriez, Inserm U1189, Lille, France
(9)
Dermatology Department, St George Clinical School, University of New South Wales, Grey Street, Sydney, 2217, Australia
(10)
The Angeles Clinic and Research Institute, 1818 Wilshire Boulevard, California, Los Angeles, USA
(11)
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
(12)
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA
(13)
Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, Al7 1TW, UK
(14)
Klinikum für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstrabe 55, 45147 Essen, Germany
(15)
Universitätsklinikum Schleswig-Holstein, Schittenhelmstr, 7, D-24 105 Kiel, Germany

Reference

  1. Sekulic A, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332. https://doi.org/10.1186/s12885-017-3286-5.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement